



PRESS RELEASE

12th September 2012

Aurobindo Pharma receives final approval for Escitalopram Oxalate Tablets

Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Escitalopram Oxalate Tablets 5mg, 10mg and 20mg (ANDA 090432), which was earlier tentatively approved. The product is ready for launch.

Escitalopram Oxalate Tablets 5mg, 10mg and 20mg are the generic equivalent of Forest Laboratories Inc's Lexapro® Tablets 5mg, 10mg and 20mg is an anti-depressant and falls under the Central Nervous System (CNS) segment. It is indicated for treatment of depression associated with mood disorders and has a market size of approximately US\$ 2.8 Billion for the twelve months ending March 2012 according to IMS.

The product has been approved out of Unit III formulations facility in Hyderabad, India

Aurobindo now has a total of 158 ANDA approvals (133 Final approvals including 1 from Aurolife Pharma LLC and 25 Tentative approvals) from USFDA

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com